Overview

Tissue Diagnostics Market is estimated to value over USD 6.7 billion by 2027 end with a CAGR of over 6% during the forecast period 2020 to 2027.

Tissue diagnostics is used for understanding tumors at a biological level which is why it is generally used for diagnosing cancer. There has been a surging demand for tissue diagnostics with a rising prevalence of cancer across the world, thereby contributing to the growth of the market. As per the data provided by the Globocan, over 14 million newly registered cancer cases and over 8 million deaths related to cancer were recorded in 2012 and it is estimated that this numbers shall reach over 17 million and over 10 million by 2021. Based on this data, the EHO and the ICRA predicted that over 19 million new cancer cases will be recorded by 2025 and this hike in the number of patients is primarily due to the increasing geriatric population. AS pe the WHO report, the geriatric population is expected to rise from over 11% in 2015 to over 21% by 2050, which shall increase the cancer patient pool, thereby proliferating the market.
Research institutes are working on automizing the tissue-based diagnosis which shall help in obtaining a faster tumor diagnosis. Furthermore, there has been a surging demand for customised medical care and with some extensive ongoing research, it will be possible to produce companion tissue diagnostic kits which is likely to positively impact the market growth. In case of the share distribution amongst market players, over 80 percent of the total market is held by five major players and due to these players have established a high level of brand loyalty which makes it difficult for emerging players to enter the market and establish their position as theses players are not at the same financial level as the established players are in terms of research infrastructure and workforce. Such factors can negatively impact the market growth during the forecast period.
There has been a significant change in the pathology sector with many clinicians shifting from traditional pathology to digital pathology, thereby allowing them to reduce the test turnaround time, enhance the outcome of patients and prioritise critical cases. For example, Alverno Laboratories in May 2019, partnered with the Royal Philips, introduced the IntelliSite Pathology Solution of Philips in their clinical labs for enhancing lab quality, patient safety and efficiency. This shall significantly boost the tissue diagnostics market growth.

Tissue Diagnostics Market

Market Segmentation:

By Product
• Consumables
o Antibodies
o Reagents
o Kits
o Probes
• Instruments
o Slide Staining Systems
o Scanners
o Tissue Processing Systems
o Other Instruments
By Technology
•   In-Situ Hybridization
•   Immunohistochemistry
•   Special Staining
•   Digital Pathology and Workflow
By Disease
•   Breast Cancer
•   Gastric Cancer
•   Lymphoma
•   Prostate Cancer
•   Non-Small Cell Lung Cancer
•   Others
By End User
•   Hospitals
•   Pharmaceutical Companies
•   Research Laboratories
•   Contract Research Organizations
•   Others
By Region
•   North America
•   Europe
•   Asia-Pacific
•   Latin America
•   Middle East and Africa

The market is classified into product, technology, disease, end user and region. The product segment is categorised into consumables and instruments. The consumables segment is predicted to hold the largest tissue diagnostics market share, and this can be attributed to an increased usage of consumables for tissue diagnostics and technological advancements in consumables for increasing their efficiency. The technology segment is fragmented into in situ hybridization, special staining, digital pathology and workflow and immunohistochemistry. The immunohistochemistry segment is anticipated to dominate the market during the forecasted timeframe. It is been widely used in the clinical R&D of cancer therapeutics and diagnostics.
Furthermore, it is mainly preferred over traditional enzyme staining methods as it is capable of providing specific tumor variations whereas the traditional techniques can only detect a limited number of protein tumors, enzymes and tissue structures. The disease segment is categorised into breast cancer, gastric cancer, lymphoma, prostrate cancer, non-small cell lung cancer and others. The breast cancer segment is predicted to lead the market owing to an increased incidence of breast cancer worldwide. This has mainly been due to unawareness regarding the development of breast cancer and unhealthy and a stressful lifestyle leading to the formation of such cancerous tumors. The end user segment is divided into hospitals, pharmaceutical companies, research laboratories, contract research organizations and others. The contract research organization segment is estimated to experience substantial growth owing to their capability of providing and managing clinical trial services, bolster research activities and aid companies facing budget constraints.

Regional Analysis:

The North America region is predicted to lead the market during the forecast period. The CDC program of Cancer Prevention and Control Research Network focusses on the steps to be taken to prevent cancer. Furthermore, there has been a rising demand for personalised medicinal methods to be implemented in the healthcare sector with a rise in the healthcare IT systems, thereby easing the adoption of sequencing methods in the region. The Asia Pacific region is predicted to grow at a substantial rate during the forecast period and this can be credited to the increased adoption of tissue diagnostic methods in the region. For example, HalioDx SAS and Genecast signed an agreement in April 2019 for commercializing the Immunoscore diagnostic assay of HalioDx in China.

Competitive Landscape:

The prominent market players included are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Siemens, Danaher, bioMérieux SA, QIAGEN, Becton Dickinson and Company, Merck KGaA, GE Healthcare, BioGenex, Cell Signaling Technology Inc., Bio SB, DiaGenic ASA, Agilent Technologies.

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key market trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the global tissue diagnostics market by product, by technology, by disease, by end user and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
• To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

•   We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•   The customization Mobility Care offered are free of charge with purchase of any license of the report
•   You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com